Class summary at a glance.

Every drug in the DPP-4 Inhibitor (Antidiabetic) class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 1tracked in Part D
CY24 Part D spend: $24.2Mcombined across class
Total Rx claims: 81K27K unique beneficiaries
Generic mfrs (active): 3across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Saxagliptin

Brand: ONGLYZA · 81K Part D claims (CY24) · 27K beneficiaries · First FDA approval: 2014-11-20

3 generic mfrs 0 plans require PA

Low NADAC$1.34

→

Avg plan cost$1.43

Part D spend $24.2M 1× spread, current vs floor

Class share

100%

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.